<DOC>
	<DOC>NCT01804257</DOC>
	<brief_summary>Feasibility study of using a digital health feedback system (DHFS) to monitor medication-taking and physiologic and behavioral parameters in patients with bipolar disorder or schizophrenia. Hypothesis: Using a digital health feedback system to characterize medication-taking behavior and activities of daily living is safe and tolerable in appropriately selected patients with bipolar disorder and schizophrenia.</brief_summary>
	<brief_title>Event Marker Ingested To Trigger Event Recorder 3.0 Psychiatry Study</brief_title>
	<detailed_description />
	<mesh_term>Schizophrenia</mesh_term>
	<mesh_term>Bipolar Disorder</mesh_term>
	<criteria>Male or female ≥ 18 and ≤ 65 years of age Meet Diagnostic and Statistical Manual of Mental Disorders (DSMIV) criteria, by Structured Clinical Interview using DSMIV SCIDI/P1, for either: i. Bipolar disorder I, II, or Not Otherwise Specified (NOS), or ii. Schizophrenia or schizoaffective disorder Clinical global impression scaleseverity (CGIS) of 3 or below Currently on a stable regimen of oral antimanic or antipsychotic medication for at least 3 months No anticipation to change or titrate the regimen in the next 28 days Willingness to adhere to study procedures Capacity to provide informed consent Pregnancy, or women of child bearing potential who are not using a medically accepted means of contraception Serious suicide or homicide risk, as assessed by evaluating clinician Unstable medical illness including cardiovascular, hepatic, renal, respiratory, endocrine, neurological, or hematological disease DSMIV diagnoses or symptoms of substance use disorders, active within the last 60 days A score of 3 or higher on the suspiciousness/paranoia item of the Brief Psychiatric Rating Scale (BPRS) Acute, clinically significant gastrointestinal symptoms, such as nausea, vomiting, abdominal pain, diarrhea, melena, or hematochezia History of significant gastrointestinal disease or major gastrointestinal surgery Clinical instability of any kind that, in the investigator's opinion, could preclude safe participation in the study Known allergies that could preclude safe participation in the study Current presence of an electronically active implanted medical device Participation in another medical device study, or on any investigational drug or device within the last 30 days Inability to obtain consent</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2013</verification_date>
	<keyword>Adherence</keyword>
	<keyword>Bipolar disorder</keyword>
	<keyword>Cellular phone</keyword>
	<keyword>Cloud computing</keyword>
	<keyword>Computers</keyword>
	<keyword>Computers, handheld</keyword>
	<keyword>Digital health</keyword>
	<keyword>Digital health feedback system</keyword>
	<keyword>Ingestion Sensor</keyword>
	<keyword>Medication adherence</keyword>
	<keyword>Medication non-adherence</keyword>
	<keyword>Medication nonadherence</keyword>
	<keyword>Mobile phone</keyword>
	<keyword>Mobile health</keyword>
	<keyword>Patient adherence</keyword>
	<keyword>Patient non-adherence</keyword>
	<keyword>Patient nonadherence</keyword>
	<keyword>Schizophrenia</keyword>
	<keyword>Telehealth</keyword>
	<keyword>Telemedicine</keyword>
	<keyword>Telenursing</keyword>
	<keyword>Wearable sensor</keyword>
</DOC>